Among 102 patients with BRCA1 GPV, a higher rate of pCR (83%) was observed after treatment with cisplatin (75 mg/m2 every three weeks for four cycles) compared to that (22%) for AC (doxorubicin and cyclophosphamide) or FAC (fluorouracil, doxorubicin, and cyclophosphamide); however, a randomized phase II study of neoadjuvant cisplatin versus AC in 118 HER2-negative BC patients with BRCA1/2 GPV (TBCRC 031) in 2020 demonstrated that the pCR or residual cancer burden (RCB) 0/1 was not significantly higher in the cisplatin-treated group than in the AC-treated group [78]. The gene discussed is ERBB2; the disease is breast cancer.